Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 19/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30626720 | 1.00 | MELK (1.00) | MELKDYRK1A | |
| Hydrochloric Acid SCHEMBL17260530 | 0.99 | MELK (0.98) | MELKDYRK1A | |
| SCHEMBL16336195 | 0.93 | MELK (1.00) | MELKDYRK1A | |
| SCHEMBL30626735 | 0.93 | MELK (1.00) | MELKDYRK1A | |
| Hydrochloric Acid SCHEMBL16337915 | 0.92 | MELK (0.98) | MELKDYRK1A | |
| SCHEMBL16336817 | 0.90 | MELK (1.00) | MELKDYRK1A | |
| Hydrochloric Acid SCHEMBL16337989 | 0.89 | MELK (0.98) | MELKDYRK1A | |
| SCHEMBL16369197 | 0.88 | MELK (0.88) | MELKDYRK1A | |
| SCHEMBL16338151 | 0.87 | MELK (1.00) | MELK | |
| Hydrochloric Acid SCHEMBL16336958 | 0.87 | MELK (0.99) | MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753329-B1 | 1,5-NAPHTHYRIDINE DERIVATIVES AS MELK INHIBITORS | ONCOTHERAPY SCIENCE INC (JP) | 2017-08-09 | — | — | EP | claimed |
| US-9345709-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-05-24 | — | — | US | claimed |
| US-9284283-B2 | Macrocyclic compounds for modulating IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2016-03-15 | — | — | US | claimed |
| US-20150328225-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-11-19 | — | — | US | claimed |
| US-9067937-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-06-30 | — | — | US | claimed |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-01-01 | — | — | US | claimed |
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | claimed |
| US-20230301973-A1 | TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA | FLOHIL JACOB ARY (NL) | 2023-09-28 | — | — | US | disclosed |
| EP-2753329-B1 | 1,5-NAPHTHYRIDINE DERIVATIVES AS MELK INHIBITORS | ONCOTHERAPY SCIENCE INC (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9345709-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-05-24 | — | — | US | disclosed |
| US-9345709-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-05-24 | — | — | US | disclosed |
| US-9345709-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2016-05-24 | — | — | US | disclosed |
| US-9284283-B2 | Macrocyclic compounds for modulating IL-17 | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2016-03-15 | — | — | US | disclosed |
| US-9067937-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-06-30 | — | — | US | disclosed |
| US-9067937-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-06-30 | — | — | US | disclosed |
| US-9067937-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-06-30 | — | — | US | disclosed |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | ENSEMBLE THERAPEUTICS CORPORATION | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328225-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NEK1, NEK5 | MELK 1/4885DYRK1A 1584/4885 |
| US-20150005319-A1 | MACROCYCLIC COMPOUNDS FOR MODULATING IL-17 | IL17A, IL15, IL2 | MELK 1672/4885DYRK1A 4678/4885 |
| US-20230301973-A1 | TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA | ABCC2, SLC2A2, ABCB1 | MELK 13/4885DYRK1A 173/4885 |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NEK1, NEK5 | MELK 1/4885DYRK1A 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.